Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;30(13):975-987.
doi: 10.2174/0113816128291955240306112558.

The Application of Nanotechnological Therapeutic Platforms against Gynecological Cancers

Affiliations
Review

The Application of Nanotechnological Therapeutic Platforms against Gynecological Cancers

Vahideh Keyvani et al. Curr Pharm Des. 2024.

Abstract

Gynecological cancers (GCs), ovarian, cervical, and endometrial/uterine cancers, are often associated with poor outcomes. Despite the development of several therapeutic modalities against GCs, the effectiveness of the current therapeutic approaches is limited due to their side effects, low therapeutic index, short halflife, and resistance to therapy. To overcome these limitations, nano delivery-based approaches have been introduced with the potential of targeted delivery, reduced toxicity, controlled release, and improved bioavailability of various cargos. This review summarizes the application of different nanoplatforms, such as lipid-based, metal- based, and polymeric nanoparticles, to improve the chemo/radio treatments of GC. In the following work, the use of nanoformulated agents to fight GCs has been mentioned in various clinical trials. Although nanosystems have their own challenges, the knowledge highlighted in this article could provide deep insight into translations of NPs approaches to overcome GCs.

Keywords: Gynecological cancers; cervical cancer; endometrial/uterine cancer; half life.; nanoplatforms; ovarian cancer.

PubMed Disclaimer

References

    1. Keyvani V.; Kheradmand N.; Navaei Z.N.; Mollazadeh S.; Esmaeili S.A.; Epidemiological trends and risk factors of gynecological cancers: An update. Med Oncol 2023,40(3),93 - DOI - PubMed
    1. Keyvani V.; Riahi E.; Yousefi M.; Esmaeili S.A.; Shafabakhsh R.; Moradi Hasan-Abad A.; Mahjoubin-Tehran M.; Hamblin M.R.; Mollazadeh S.; Mirzaei H.; Gynecologic cancer, cancer stem cells, and possible targeted therapies. Front Pharmacol 2022,13,823572 - DOI - PubMed
    1. Piechocki M.; Koziołek W.; Sroka D.; Matrejek A.; Miziołek P.; Saiuk N.; Sledzik M.; Jaworska A.; Bereza K.; Pluta E.; Banas T.; Trends in incidence and mortality of gynecological and breast cancers in Poland (1980-2018). Clin Epidemiol 2022,14,95-114 - DOI - PubMed
    1. Gultekin M.; Dundar S.; Kucukyildiz I.; Karaca M.Z.; Boztas G.; Turan S.H.; Hacikamiloglu E.; Keskinkilic B.; Survival of gynecological cancers in Turkey: Where are we at? J Gynecol Oncol 2017,28(6),e85 - DOI - PubMed
    1. Wang Q.; Peng H.; Qi X.; Wu M.; Zhao X.; Targeted therapies in gynecological cancers: A comprehensive review of clinical evidence. Signal Transduct Target Ther 2020,5(1),137 - DOI - PubMed

Substances

LinkOut - more resources